mRNA expression in low grade serous ovarian cancer: Results of a nanoString assay in a diverse population
| Autor: | Alex Sanchez Covarrubias, S.E. Jordan, Andre Pinto, Sophia George, Heba Saad, Matthew Schlumbrecht, J. Matt Pearson, Brian M. Slomovitz, John Siemon, Marilyn Huang |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Adult
0301 basic medicine Oncology Neuroblastoma RAS viral oncogene homolog medicine.medical_specialty Population medicine.disease_cause Article Proto-Oncogene Proteins p21(ras) Young Adult 03 medical and health sciences 0302 clinical medicine Tubulin Internal medicine Biomarkers Tumor medicine Humans RNA Messenger Registries Progression-free survival HRAS education Germ-Line Mutation Aged Retrospective Studies Xeroderma Pigmentosum Group D Protein Ovarian Neoplasms education.field_of_study business.industry Gene Expression Profiling Obstetrics and Gynecology Middle Aged Progression-Free Survival Cystadenocarcinoma Serous Serous fluid 030104 developmental biology 030220 oncology & carcinogenesis Female KRAS RNA extraction ERCC1 business |
| Zdroj: | Gynecol Oncol |
| ISSN: | 0090-8258 |
| DOI: | 10.1016/j.ygyno.2020.08.030 |
| Popis: | Objective Mutations in the MAP kinase pathway (KRAS, NRAS, BRAF) are common in low grade serous ovarian carcinoma (LGSOC). The effect of these and other mutations on RNA transcription in this disease is poorly understood. Our objective was to describe patterns of somatic mutations and gene transcription in a racially diverse population with LGSOC. Methods Utilizing an institutional tumor registry, patients with LGSOC were identified and charts were reviewed. RNA was extracted from available tumor tissue. Commercial tumor profiling results were analyzed with PanCancer pathway nanoString mRNA expression data. Along with nanoString n-Solver software, Chi-squared, Fishers Exact, and Cox proportional hazards models were used for statistical analysis, with significance set at p Results 39 patients were identified—20% Black, 43% Hispanic, and 36% non-Hispanic White. 18 patients had commercial somatic DNA test results, and 23 had available tumor tissue for RNA extraction and nanoString analysis. The most common somatic alterations identified was KRAS (11 patients, 61%), followed by ERCC1 and TUBB3 (9 each, 50%). KRAS mutations were less common in smokers (14.3% vs 90.9%, p = 0.002). RNA expression analysis demonstrated a greater than two-fold decrease in expression of HRAS in tumors from older patients (p = 0.04), and a greater than two-fold decrease in the expression of HRAS in recurrent tumors (p = 0.007). No significant differences were seen in somatic testing results, RNA expression analysis, or progression free survival between different racial and ethnic cohorts. Conclusions Somatic deficiencies in ERCC1, TUBB3, and KRAS are common in LGSOC in a population of minority patients. HRAS demonstrates decreased expression in tumors from older patients and recurrent tumors. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect